Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10552806
Filing Date		2005-10-11
First Named Inventor BERN		IHARD GLEICH
Art Unit		
Examiner Name		
Attorney Docket Number		DE030116

				U.S.	PATENTS		Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹ Issue Date Name of Patentee or Applicant of cited Document		Releva	Columns, nt Passas Appear	Lines where ges or Relevan	
	1	4136683		1979-01-30	GORDON			
	2	4267234		1981-05-12	REMBAUM			
	3	4452773		1984-06-05	MOLDAY			
	4	4554088		1985-11-19	WHITEHEAD ET AL			
	5	6082366		2000-07-04	ANDRA ET AL			
If you wis	h to a	dd additional U.S. Paten	t citatio	n information pl	lease click the Add button.		Add	
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove	
Examiner Cite No Publication Number Kind Code ¹ Publication Name of Patentee or Application of cited Document		Name of Patentee or Applicant of cited Document	Releva		Lines where ges or Relevan			
	1							

FOREIGN PATENT DOCUMENTS

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Examiner Cite Foreign Document Country

Application Number		10552806
Filing Date		2005-10-11
First Named Inventor BERN		IHARD GLEICH
Art Unit		
Examiner Name		
Attorney Docket Numb	er	DE030116

Name of Patentee or

Pages,Columns,Lines

where Relevant

Initial*	No	Number ³	Code ² j	Code ⁴	Date	Applicant of cited Document	Passages or Relevant Figures Appear	Τs
	1	3751918	DE	T2	1997-03-20	ADVANCED MAGNETICS		
	2	0095124	EP	A1	1983-05-17	BRUKER ET AL		
	3	1304542	EP	A2	2002-10-17	KPENV		
	4	10151778	DE	A1	2003-05-08	PHILIPS CORP IP		
If you wis	h to a	dd additional Foreign P				lease click the Add butto		
	_				RATURE DO		Remove	
Examiner Initials* Cite No Include name of the author (in CAPITAL LETTERS), titl (book, magazine, journal, serial, symposium, catalog, et publisher, city and/or country where published.		catalog, etc), o			T5			
	J. M. PEREZ: "DNA-BASED MAGNETIC NANOPARTICLE ASSEMBLY ACTS AS A MAGNETIC RELAXATION NANOSWITCH ALLOWING SCREENING OF DNA-CLEAVING AGENTS, MGH-CENTER FOR MOLECULAR MAGNET RESEARCH, HAVAVRAN BEDICALS, SCHOOL, 12-14-201, VOL. 12, NO. 12.							
	2	W. S. HINSHAW; "IMAG METHOD", DEPT. OF F				IC RESONANCE: THE SEN L. 47, NO. 8, 8/1976.	SITIVE-POINT	
	3	LEE JOSEPHSON ET A SEQUENCES", ANGEV				HE DETECTION OF OLIGO	DNUCLEOTIDE	

Kind Publication

	Application Number		10552806
	Filing Date		2005-10-11
NFORMATION DISCLOSURE	First Named Inventor	Inventor BERNHARD GLEICH	
STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	Art Unit		
	Examiner Name		
	Attorney Docket Numb	er	DE030116

5	

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

18ee Kint Code of USPTO Petert Documents at Innex/ISPTO.GOLY or MPEP 901.04. 2 Enter office that issued the document, by the Innovative of Kint Operation (WIPO) Standard 51.3.) 17ee Legateses patient for comment, the included on the year of the register or interpretate the serial uniform the Depart comment.

Inno of Cocument by the opportunities pretools as endicated on the document under WIPO Standard 51.16 if possible. **Applicant is to place a check mark here if English languages translation is stated.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10552806
Filing Date		2005-10-11
First Named Inventor BERN		IHARD GLEICH
Art Unit		
Examiner Name		
Attack Dealest News		DE020446

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98	to make the ap	ppropriate selection(s);
---------------	----------	----------	----------------	--------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(4)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/MICHAEL E. MARION/	Date (YYYY-MM-DD)	2007-09-25
Name/Print	MICHAEL E MARION	Registration Number	32266

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5.1.S.C. 12.04 and 3T CFR.

1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence; P.O. Box 1450, Alexandria, V.S. 231-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2211-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.